Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of rapcabtagene autoleucel versus rituximab in severe refractory diffuse cutaneous systemic sclerosis
jRCT2013240056Phase 2Suspended
- Sponsor
- Novartis
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, open-label trial in systemic sclerosis (SSc) comparing Rapcabtagene autoleucel with Rituximab active comparator (2 arms). Primary endpoint: Achievement of treatment response by rCRISS50 at Week 52. Started Dec 2024; status: suspended.
02
Drugs
rapcabtagene autoleucelrituximab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on jRCT2013240056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2013240056.